This site is intended for UK HCPs* and ORDMs** and is brought to you by Pfizer Ltd.

Menu
Close
FormulationsCOMIRNATY LP.8.1 30mcgCOMIRNATY LP.8.1 10mcg COMIRNATY LP.8.1 3mcg

The information on this website relates to storage, preparation and administration of COMIRNATY vaccines used as part of the UK National Immunisation Programme.
For information regarding private provisions of COMIRNATY vaccines please visit PfizerPro:

www.Pfizerpro.co.uk/medicine/comirnaty

For more information relating to Pfizer’s vaccines and related therapy areas, including clinical publications and resources, as well as assets relating to particular at-risk groups, please visit:
https://pfizermedical.pfizerpro.co.uk/vaccines

 

There are several formulations of COMIRNATY vaccine used as part of the current programme. These are summarised in the table below, with more information on the product pages. To verify that you have selected the correct vaccine, observe the key aspects of the pack and vial label for the formulation before administration.


COMIRNATY Vaccine Formulation Quick Reference Guide for use on the National Immunisation Programme.
 
Click here
Click here
Click here
Name
COMIRNATY LP.8.1 30 micrograms/dose dispersion for injection pre-filled syringe COVID-19 mRNA Vaccine 1 
COMIRNATY LP.8.1 10 micrograms/dose dispersion for injection single dose vial COVID-19 mRNA Vaccine 2 
COMIRNATY LP.8.1 3 micrograms/dose dispersion for injection 3 dose vial COVID-19 mRNA Vaccine 3 
Licensed age of use
12 years and older 1
5 to 11 years old 2
6 months to 4 years old3
One Dose Contains
30 micrograms mRNA encoding LP.8.1 1
10 micrograms mRNA encoding LP.8.1 2
3 micrograms mRNA encoding LP.8.1 3
Pack image
Dilution Status
Ready for use†. Do not dilute1
Ready for use†. Do not dilute2
Dilute before use3
Doses per vial/syringe
1 dose of 0.3mL 1
1 dose of 0.3mL 2
3 doses of 0.3mL after dilution 3
Dilution Volume
Do not dilute prior to use.
Do not dilute prior to use.
Dilute in its original vial with 1.1 mL sodium chloride 9 mg/mL (0.9%) solution.
Link to product resources
†It is expected that the majority of vaccinating sites will receive this vaccine thawed and stored at 2 °C to 8 °C, ready for use.

Information about COMIRNATY® KP.2▼ (cemivameran) COVID-19 mRNA Vaccine / 30mcg dose dispersion for injection can be found here

Information about COMIRNATY® JN.1▼ (bretovameran) COVID-19 mRNA Vaccine / 30mcg dose dispersion for injection can be found here

Information about COMIRNATY® JN.1▼ (bretovameran) COVID-19 mRNA Vaccine / 10mcg dose dispersion for injection can be found here

Information about COMIRNATY® JN.1▼ (bretovameran) COVID-19 mRNA Vaccine / 3mcg dose concentrate for dispersion for injection can be found here
Mechanism of Action and Composition:
  • mRNA encoding LP.8.1 is single-stranded, 5'-capped-messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (mRNA encoding LP.8.1). 1-3
  • The nucleoside-modified mRNA in COMIRNATY is formulated in lipid nanoparticles, which enable delivery of the non-replicating RNA into host cells to direct transient expression of the SARS-CoV-2 S antigen.1-3
  • The vaccine elicits both neutralising antibody and cellular immune responses to the spike (S) antigen, which may contribute to protection against COVID-19. 1-3
References:
  1. Comirnaty LP.8.1 30 micrograms/dose dispersion for injection in pre-filled syringe 12+ years COVID-19 mRNA Vaccine Summary of Product Characteristics. Available athttps://www.medicines.org.uk/emc/product/101150/smpc (accessed: February 2026)                                                                                                                                                             
  2. Comirnaty LP.8.1 10 micrograms/dose dispersion for injection single dose vial children 5-11 years COVID-19 mRNA Vaccine Summary of Product Characteristics. Available at https://medicines.org.uk/emc/product/101151  (accessed: February 2026)
  3. Comirnaty LP.8.1 3 micrograms/dose concentrate for dispersion for injection 3-dose vial children 6 months - 4 years COVID-19 mRNA Vaccine Summary of Product Characteristics. Available athttps://medicines.org.uk/emc/product/101152 (accessed: February 2026)        
PP-CMR-GBR-0990. February 2026

Marketing Authorisation
Holder: BioNTech
Manufacturing GmbH

COMIRNATY COVID-19 mRNA vaccines, which are based on BioNTech proprietary mRNA technology, were developed by both BioNTech and Pfizer.

©2026 Pfizer Inc. All rights reserved. PP-CMR-GBR-1031. March 2026

*Healthcare Professionals ** Other Relevant Decision Makers

The product information provided in this site is intended only for Healthcare Professionals and Other Relevant Decision Makers resident in United Kingdom.

This website is brought to you by Pfizer Limited, a company registered in England and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent CT13 9NJ, VAT registration number GB201048427.

The products discussed may have different product labelling in other countries.

For Healthcare Professionals* and Other Relevant Decision Makers** only

This website is not intended for patients or for members of the general public. The website contains promotional content.

I confirm that I am a Healthcare Professional* or Other Relevant Decision Maker** resident in the United Kingdom.

If you select Yes – United Kingdom: you will be directed to the United Kingdom*** homepage. Information on this page is aligned to the Summary of Product Characteristics (SmPC) for the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition of Healthcare Professional is members of the medical, dental, pharmacy and nursing professions and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

**The ABPI Code definition of ‘Other Relevant Decision Makers’ particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.

*** United Kingdom includes England, Scotland, Wales and Northern Ireland


PP-CMR-GBR-0940. August 2025